IMX101
Small Cell Lung Cancer
PreclinicalActive
Key Facts
About Imunexus Therapeutics
Australian biotech that 'turbo‑charges' existing biologics into multispecific therapeutics for oncology and neuro‑immune diseases.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| LNTH-2503 | Lantheus Medical Imaging | Phase 1 |
| Small Cell Lung Cancer (SCLC) FFPE | The MT Group | N/A - Service |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Discovery Program | Disco Pharmaceuticals | Discovery |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase III |
| SCLC Program | Arcellx | Discovery |
| APG-1252 (Pelcitoclax) | Ascentage Pharma Group | Phase 1/2 |
| zocilurtatug pelitecan (ZL-1310) | Zai Lab | Phase 3 |